Cell Biotech Co

Cell Biotech Co Long-term Debt

The Long-Term Debt of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 366.66 M KRW. In the previous year, Long-Term Debt was 934.17 M KRW — a change of -60.75% (lower).

Long-term Debt

366.66 MKRW

YoY

-60.75%

Last updated:

Long-Term Debt of Cell Biotech Co is 2024 366.66 M KRW. Long-Term Debt of Cell Biotech Co was 2023 934.17 M KRW. It decreases by -60.75% lower compared to the previous year.

The Cell Biotech Co Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2017
0.00 KRW
Jan 1, 2018
0.00 KRW
Jan 1, 2019
512.08 M KRW
Jan 1, 2020
686.44 M KRW
Jan 1, 2021
423.49 M KRW
Jan 1, 2022
357.79 M KRW
Jan 1, 2023
934.17 M KRW
Jan 1, 2024
366.66 M KRW
The Cell Biotech Co Long-term Debt history
YEARLong-term DebtYoY
366.66 MKRW-60.75%
934.17 MKRW+161.09%
357.79 MKRW-15.51%
423.49 MKRW-38.31%
686.44 MKRW+34.05%
512.08 MKRW—
0.00KRW—
0.00KRW—
0.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Long-Term Debt of Cell Biotech Co is 366.66 M KRW in 2024.

Long-Term Debt of Cell Biotech Co changed from 934.17 M KRW to 366.66 M KRW, representing a -60.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Cell Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cell Biotech Co

All Key Metrics — Cell Biotech Co